Jump to section
To end preventable disease in dogs by providing DNA testing to dog owners, breeders, and veterinarians.
Few candidates hear
back within 2 weeks
-35% employee growth in 12 months
Embark provides DNA testing for dogs, offering test kits to dog owners, breeders, and veterinarians to help them understand the specific health needs of each dog. The company also provides health kits that facilitate screening for over 215 potential conditions, with any findings being sent directly to the dog's vet.
Whilst the company will face competition from other dog DNA test providers such as Wisdom Panel, Embark shows potential to compete in the market with its broad focus on discovering breeds, screening dogs for health issues, and helping customers locate their dog's relatives. There is a huge opportunity in the market, with the US spending on pets reaching $123.6 billion in 2021.
The company has seen huge growth in the last few years and attracted considerable investment. Setting out to be the standard care for dog owners and vets, Embark will be focusing on expanding its database and team.
Kirsty
Company Specialist at Welcome to the Jungle
Jul 2021
$75m
SERIES B
Apr 2019
$10m
SERIES A
This company has top investors
Ryan Boyko
(Co-Founder & CEO)Experience as an Independent Researcher for Cornell University's Cornell Village Dog Diversity Project from 2007 to 2012. Studied Epidemiology of Microbial Diseases at Yale University.
Adam Boyko
(Co-Founder & CSO)Experience as a Research Associate for Stanford University School of Medicine. Associate Professor at Cornell University since 2011.
Matt Salzberg
(Co-Founder)Experience as Founder, CEO, and Chairman of Blue Apron from 2011 to 2021. Managing Partner of Material since 2018.